Four-Stage Audit Demonstrating Increased Uptake of HIV Testing in Acute Neurology Admissions Using Staged Practical Interventions

Dilraj Singh Sokhi1,*, Chantal Oxenham1, Rebecca Coates1, Mhairi Forbes1, Nadi K. Gupta2, Daniel J. Blackburn1,3

1 Department of Clinical Neurology, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, South Yorkshire, United Kingdom, 2 Department of Genito-Urinary Medicine, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom, 3 Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, South Yorkshire, United Kingdom

¤ Current address: L16 Doctors Office, Department of Clinical Neurology, Royal Hallamshire Hospital, Sheffield Teaching Hospital NHS Foundation Trust, Glossop Road, Sheffield, South Yorkshire, S10 4JF, United Kingdom

* Dilraj.Sokhi@doctors.net.uk

Abstract

Background
UK National Guidelines (UKNG) advise HIV testing in clinically indicated neurological presentations. We audited the impact of our practical strategies to increase uptake of HIV testing at a regional acute neurology admissions unit.

Methods
We audited HIV testing in 4 periods over 2 years: before we designed a UKNG-based “HIV testing in Neurology” protocol (“pre-protocol”); after dissemination of the protocol alone (“post-protocol”); post-protocol dissemination combined with both a tailored departmental admissions clerking proforma to prompt for HIV testing & consenting, and regular focussed tutorials to doctors on HIV testing in neurological patients (“post-proforma”); and finally one year after the post-proforma period (“+1 year”). We also looked at the total number of HIV tests sent from the unit during the two-year period. We assessed significance using Fisher’s exact test.

Results
47.8% of all acute neurology non-stroke admissions were eligible for HIV testing during all the audit periods. Testing rates were as follows: pre-protocol 21.9%; post-protocol 36.6%; post-proforma 83.3%; and at +1 year 65.4% (p<0.05 for both post-protocol and +1 year when compared to pre-protocol). Documentation of consent for HIV testing improved from 25% to 67.6% with the HIV-tailored clerking proforma. The total number of HIV tests
requested from the unit doubled in the post-proforma period compared to pre-protocol (p<0.05).

**Conclusion**

In conclusion: the combination of an HIV testing protocol, a tailored departmental clerking proforma and regular focussed teaching to doctors on indications for HIV testing led to a sustained increase in HIV testing uptake in our regional acute neurology admissions unit.

---

**Introduction**

The prevalence of Human Immunodeficiency Virus (HIV) infection in the UK has increased by 25% over five years to an estimated 98,400 people [1]. Early diagnosis is vital as commencing combined anti-retroviral therapy before severe immunosuppression can lead to a near-normal life expectancy [2, 3]. Early knowledge of HIV status also helps change behaviour that reduces HIV transmission to partners [4, 5], which has sizeable health-cost savings: prevention of one HIV infection saves approximately £0.3 million of public funds [6]. Yet one in five, and in some high-risk groups up to a third, of people with HIV are unaware of their diagnosis in the UK [1]. Those diagnosed "late" with HIV (CD4<350 cells/μL) have a worse prognosis [7], and up to a quarter of deaths can be attributed to missed opportunities by healthcare workers to test at an earlier stage [8, 9].

Opt-out HIV testing in all patients is recommended in the USA [10]. The UK National Guidelines for HIV testing (UKNG) 2008 were developed to help normalise and expand HIV testing across healthcare services [11]. Testing all hospitalised patients for HIV, regardless of local prevalence and risk factors, is feasible and cost-effective in the UK and well accepted amongst patients [12–14]. However, the UKNG advocate routine testing only where local diagnosed prevalence is 2/1000 or greater.

Opt-out routine testing rates in “traditional” settings such as sexual health and ante-natal clinics have increased substantially since the UKNG [15]. There has also been some success in other “non-traditional” settings in the UK and Europe [16–28] (see Table 1).

Dissemination of UKNG using conventional methods alone–presenting at medical “grand rounds”, via letter and email, posting guidelines on wards and doctors’ offices–has been shown to have little impact on uptake of HIV testing even in high sero-prevalent areas such as London and Blackpool [19, 22]. More robust publicity, providing multi-lingual patient information leaflets, focussed tutorials for frontline testing staff, admission proforma prompts for HIV testing, regular on-site support by HIV staff, and using trained individuals to obtain consent and blood samples have been shown to be more successful [16–18, 20, 21].

The UKNG clinical indicator conditions include neurological presentations of HIV infection. HIV enters the nervous system early during acute infection and can affect any part of the nervous system; 10% of HIV sero-conversion presentations are neurological, usually as an aseptic meningo-encephalitis [29]. Therefore, a pure neurological presentation of HIV is an opportunity to diagnose the infection at an early stage; indeed, it is recommended to test for HIV in all patients with suspected encephalitis [30].

The Department of Clinical Neurology in Sheffield, South Yorkshire, is a tertiary centre which admits patients with acute neurological presentations, including strokes. There are approximately 3,500 acute admissions per year, of which 50–60% are discharged within 48 hours (cases such as uncomplicated exacerbations of seizures, acute headaches, multiple
sclerosis relapses and medical decompensation of chronic neurological disorders). The prevalence of HIV in Yorkshire has trebled over the last decade, and Sheffield’s HIV prevalence has risen from 1.4 to 1.8/1000 [31]. In late 2010 a middle-aged patient was transferred from a district general hospital, but the HIV-related diagnosis causing the neurological decline was not realised until three months later, at which point their CD4 count was 13. This prompted collaboration with the local Genito-Urinary Medicine department to improve HIV testing in eligible acute neurology patients, and a local “HIV Testing in Neurology” protocol was devised, based on the UKNG (Fig 1).

**Materials and Methods**

We prospectively reviewed medical notes for patients admitted as acute non-stroke neurology cases over four time periods:

---

**Table 1. Summary of studies aimed at improving HIV testing uptake in “non-traditional” settings.**

| Study | Setting | Pre-study interventions | Study Periods | Results |
|-------|---------|-------------------------|---------------|---------|
| Ellis et al, 2011 [16]: acute medical admissions (Newcastle) | Specialist-led seminar and tutorials, pre-test patient leaflet, 1-page HIV proforma | 14th September–26th October 2009: Junior doctors did 91.1% of tests; 4th January–19th March 2010: Clinical assistant did 78.9% of tests | 478/3753 approached (12.7%); 396/478 consented (82.8%) | 2 |
| Palfreeman et al, 2013 [17]: Acute Medical Admissions Unit (Leicester) | Consultants emailed, junior doctors’ induction, AMU staff trained | “Pre-pilot”: September 2008–August 2009 | 205/5484 tested (3.7%) | 4 |
| Phillips et al, 2014 [18]: Acute Medical Admissions Unit (Croydon) | Specialist-led seminar and tutorials, consultants emailed, juniors’ induction, AMU staff trained, intranet updates, patient posters and admission packs, HIV-tailored proforma | Jul 2011 –Mar 2013 Weekly visits to AMU by HIV team for first 3 months | 4122/12682 tested (32.5%) | 14 |
| Peck et al, 2010 [19]: Acute Admissions Unit (UCL, London) | Intranet guideline, consultants informed, trainee tutorial | 15th April–18th July 2008 | 16/56 tested (28.6%) | 1 |
| Rayment et al, 2012 [20] HIV in non-traditional settings (the HINTS study): all study sites in London | (Chelsea & Westminster Emergency Department) Seconded staff, sexual health department support, non-clinical testers | August–November 2009 | 3433/5505 approached (62.4%); 2121/3433 consented (61.8%) | 4 |
| | (Homerton Acute Care Unit) Seconded staff from various departments | January–April 2010 | 548/1298 approached (42.2%); 384/548 consented (70.1%) | 4 |
| | (Kings College Dermatology clinic) Two student HIV testers offering test pre-clinic | July–September 2010 | 1329/5352 approached (24.8%); 1002/1329 consented (75.4%) | 0 |
| | (North End Primary Care Medical Centre) Practice clinical staff had focussed training; testing introduced in a staggered fashion | February—May 2010 | 884/1700 approached (52%); 598/884 consented (67.6%) | 0 |
| Perry et al, 2010 [27]: Acute General Medicine (Brighton) | | August–December 2009 | 1190/2735 tested (43.5%) | 2 |
| Alston et al, 2013 [28]: Acute admissions (Surrey & Sussex) | | 2011 | 1% in high-prevalence areas; 3% in low-prevalence areas (out of 200 case notes reviewed) | ? |

---

doi:10.1371/journal.pone.0134574.t001
HIV Testing in Neurology

HIV testing in Neurology Protocol

Irrespective of patient’s age, gender and ethnicity:
Test ALL with:
- Cryptococcal Meningitis
- Cerebral Abscess
- Cerebral Toxoplasmosis
- Aseptic Meningitis
- Encephalitis
- Leukoencephalopathy (including Progressive Multifocal)
- Primary cerebral lymphoma
- Space occupying lesion of uncertain cause
- Any neurological symptoms with possible seroconversion (fever, pharyngitis, rash, etc)

CONSIDER testing if:
- Unexplained peripheral neuropathy
- Guillain Barre Syndrome / CIDP (especially if lymphocytic CSF)
- Myositis
- Transverse Myelitis
- Dementia (especially if subcortical, or abnormal white matter)

DOCUMENT REASON IF TEST NOT PERFORMED

“We do a number of routine tests including for HIV is that ok?”
(Formal pre-test counselling not required—verbal consent sufficient)

DOCUMENT VERBAL CONSENT IN NOTES
If patient requests more information, provide information leaflet
(Or contact genito-urinary (GUM) / infectious diseases (ID) dept - below)

REQUEST HIV TEST → yellow-top blood bottle
(“Category 3 risk” sticker NOT required)

NEGATIVE
If high risk for HIV or suspected seroconversion illness:
REPEAT TEST IN 3 MONTHS

POSITIVE
CONTACT GUM OR ID SPR
(on-call via switchboard; or GUM ext. 13528)
Patient will be seen within 24 hours
1. “Pre-protocol”, 30th July–31st August 2012: before the protocol was first disseminated to clinical staff;

2. “Post-protocol”, 19th October–10th November 2012: after the protocol was emailed to all departmental consultants and frontline staff, and copies placed on ward noticeboards, in doctors’ offices and on notes trolleys;

3. “Post-proforma”, 10th June 2013–1st August 2013: 2 months after altering the neurology departmental clerking proforma to prompt on consenting and testing for HIV in eligible patients. We did this by adding the questions “Is HIV testing indicated? Yes/No” and “If indicated, consent obtained? Yes/No” into the mandatory statements section (this section also includes prompts for venous thromboprophylaxis, decision for resuscitation procedures and cognitive screening). Implementation of the new proforma in April 2013 coincided with the rotation of new junior doctors starting at the hospital. At the hospital induction, we educated doctors about the importance of HIV testing in acute neurology patients and reinforced this with a focussed tutorial in May 2013.

4. “+ 1 year”, 28th May–20th July 2014: we continued with the interventions of stage (3.) above every doctors’ rotation, and re-audited at the end of one year.

We aimed to review a minimum of 60 case-notes during each audit period after the protocol was disseminated, and collected data as to whether:

1. the patient was eligible for an HIV test;

2. the HIV test was undertaken, and if so what the result was;

3. consent was documented;

4. the eventual diagnosis was an indicator condition.

In addition, in order to measure the effect of our interventions on overall uptake of HIV testing within our acute neurology service, we cross-referenced all HIV tests undertaken within the hospital Trust, held on a database by the Department of Virology, with our electronic database of all acute admissions including stroke for the period 1st June 2012–31st August 2014.

All data were inputed and analysed on Microsoft Excel.

Ethical Approval

The project was a service evaluation and quality improvement initiative by the Sheffield Teaching Hospitals NHS Foundation Trust Clinical Effectiveness and Audit Unit (CEAU). Formal ethical approval by the local research ethics board was therefore not required.

Patient Consent

We strictly adhered to the UKNG for patient consent during HIV testing: indications for HIV testing were explained to all patients before undertaking the test, and for those patients who lacked capacity at the time of testing, a medical decision was made based on the patient’s best interests. As per UKNG guidelines, consent was documented in the acute admissions clerking Fig 1. The Sheffield “HIV Testing in Neurology” protocol. Based on the UKNG Guidelines for HIV testing. We have previously presented preliminary data from an audit of the effectiveness of this protocol alone in improving HIV testing [32]. We evaluated efficacy of improving HIV testing in eligible patients by re-auditing our service after changing the neurology admission proforma and introduced training sessions. We also studied the total number of HIV tests sent from the acute neurology unit.

doi:10.1371/journal.pone.0134574.g001
proforma using “Yes/No” answers. For those patients who lacked capacity to consent for HIV testing but in whom testing was definitely indicated, the test was still undertaken by the consultant’s team if it was deemed to be in the best interests of the patient.

The CEAU indicated that specific consent for this service evaluation study was not required as we were following local Trust guidelines on information governance and patient confidentiality including in the context of “sensitive diseases” such as HIV. The procedures for consent for HIV testing as above were accepted by the CEAU.

We followed the SQUIRE Guidelines (www.equator-network.org) throughout this quality improvement study. The project was in keeping with the principles of the Declaration of Helsinki.

Results
There were 6723 admissions over 2 years and 2 months: 4349 (64.6%) were acute non-stroke neurology admissions, 928 (13.8%) were acute stroke admissions, and the rest were elective admissions. All patients approached for HIV testing accepted to have the test, giving a patient uptake rate of 100%. There were no positive HIV tests throughout the audit period.

Table 2 summarises the results of the audit, and the diagnoses of patients in whom HIV test was indicated are shown in Table 3. "Post-protocol" testing of eligible patients was higher at 36.6% compared to 21.9% during the “pre-protocol” period, and highest during the “post-proforma” period at 83.3% but this reduced to 65.4% at “+1 year”. Overall HIV testing rates during the casenotes audit periods (and for all admissions) consistently increased through the two years, from 12.3% (9.0% for all admissions) during “pre-protocol”, to 18% (20.4%) during “post-protocol”, then to 33.9% (23.4%) during “post-proforma” and finally to 28.3% at “+1 year”. 70 of the 80 eligible patients during the casenotes audit period had UKNG clinical indicator diseases.

Table 2. Results of the four stages of the audit.

|                      | “Pre-Protocol” | “Post-Protocol” | “Post-Proforma” | “+1 year” |
|----------------------|---------------|----------------|-----------------|-----------|
| Admissions 1 Sep 2012–2 Apr 2013 | Audit 30 Jul–31 Aug 2012 | Admissions 19 Oct–10 Nov 2012 | Admissions 3 Apr 2013–1 Aug 2014 | Audit 10 Jun–1 Aug 2013 |
| Audit 28 May–20 Jul 2014 |
| Patients admitted | 392 | 136 | 1109 | 111 | 2848 | 120 | 119 |
| Patients admitted >48 hours | 201 | 73 | 481 | 61 | 1120 | 59 | 60 |
| Median age in years (range) | 53(20–87) | 52 (17–95) | 53 (16–90) | 59 (28–95) |
| HIV test indicated | 18 | 9 | 98 | 11 | 262 | 20 | 17 |
| HIV test performed | 0 | 5 | 15 | 10 |
| Consent documented | 9.0% a,b | 12.3% | 20.4% a | 18.0% | 23.4% b | 33.9% | 28.3% |
| Eligible testing rate | 21.9% c,d | 36.6% a | 83.3% c,e | 65.4% d |

Two-tailed Fisher’s exact test statistically significant at p<0.05 when comparing:

a-b overall HIV testing rates between the “pre-proforma” and both “post-proforma” (a) and “post-protocol” (b) periods

æ–å proportion of HIV testing in eligible patients during case-notes audit between: “pre-proforma” and “post-protocol” (c); “pre-proforma” and “+1 year”; and “post-proforma” and “post-protocol” (e) periods

doi:10.1371/journal.pone.0134574.t002
Discussion/Conclusion

This is the first study investigating the effect of practical simple interventions to improve HIV testing uptake in neurology patients, whom are an important group as they include several conditions that can be result of acute seroconversion and chronic HIV infection. Compared to similar studies in other non-traditional settings (Table 1), we additionally measured the sustained effect of our interventions with a fourth stage of re-audit.

47.8% of our patients during the audit periods were eligible for HIV testing, compared to 15–28% of unselected acute medical admissions presenting with neurological problems [18, 33], which reflects the nature of acute neurological cases presenting to our neurology unit. The overall testing rate for all patients after introduction of the protocol, assuming a similar eligibility rate for testing throughout the post-protocol period, came to 19% which is comparable to other studies. Dissemination of the HIV testing protocol on its own increased uptake by a modest 15%, similar to previously reported studies [19, 22], although this is better than having no departmental UKNG-based protocol as a recent study of HIV testing in intensive care patients within our hospital Trust found a testing rate of <5% in eligible patients [34].

The proportion of eligible acute neurology and stroke patients who were tested for HIV doubled from the pre-protocol period to 20.4%, and continued to increase in the final audit period to 23.4%. The combined effect of our protocol, regular focussed teaching for admitting staff, and altering the admission clerking proforma increased testing uptake 3.7-fold to a maximum of 83%. The effect was sustained at a lower rate of 65% when audited one year later; this is comparable to 66.8% from the HINTS study [20]. This plateauing effect has been seen e.g. in the Croydon study, where after the initial intensive period of training clinical staff the rate peaked to 41.3% but then settled to 32.5% [18], partly attributed to the rapid turnover of staff in acute medical settings. (The testing rates during our case-notes audit period are almost twice as high as those reported in other acute settings probably due to the smaller numbers of cases [16–18, 27]). Since the “post-proforma” period, the HIV testing protocol is included as mandatory introductory material for junior doctors during our departmental induction session at the

| Table 3. Clinical presentations of patients eligible for HIV based on the Sheffield testing protocol. |
|---------------------------------------------------------------|
| Unexplained peripheral neuropathy                          | 15 |
| Leukoencephalopathy / atypical demyelination               | 13 |
| Encephalitis                                                | 9  |
| Transverse Myelitis                                         | 7  |
| Space occupying lesion of unknown cause                     | 7  |
| Guillain-Barre syndrome                                     | 7  |
| Myositis                                                    | 5  |
| Atypical dementia                                           | 4  |
| Aseptic meningitis                                          | 3  |
| **Other:**                                                  |    |
| Atypical optic neuritis          a                        | 4  |
| Unexplained ataxia         b                             | 3  |
| Complicated headaches           c                        | 3  |
| **Total**                                                | **80** |

a as defined by the “atypical optic neuritis” protocol (see discussion section)
b as a national ataxia centre, HIV testing was done on these patients after applying our departmental ataxia investigation panel
c headaches with cranial nerve involvement or other neurological features

doi:10.1371/journal.pone.0134574.t003
begin of their rotation. However, we found that one of the key interventional differences between the “post-proforma” and “+1 year” periods was that the focussed training of junior doctors regarding HIV testing was occurring towards the middle or end of their rotation in the “+1 year” period, rather than towards the beginning as was the case during the “post-proforma” period. The co-incident induction and focussed teaching during the post-proforma probably had a synergistic effect to increasing awareness of HIV testing amongst the new junior doctors. Therefore, to counter the plateauing effect, we will ensure that the focussed teaching returns to occurring within the first few weeks of the start of the rotation.

In the “post-protocol” period, the overall testing rate was 23.4% but in the audit period was slightly higher at 33.9%. This could be as a result of the more active interventions (focussed seminars and teaching sessions, awareness of the role out of the new proforma) in addition to the relatively passive intervention of disseminating the HIV testing protocol. These more dynamic interventions are more likely to have enthused the new house of junior medical staff during the audit period which is reflected in the high number of cases tested for HIV; such effects have been noted in other studies [17, 18]. This may also be the reason why 100% of patients approached consented to have their HIV status checked, as compared to 61.8%-82.8% acceptance rates in other studies [16, 20]. Taking the quoted estimated HIV prevalence of approximately 2 per 1000 in South Yorkshire, we would have expected to have 4 patients tested positive. No new HIV cases were encountered during our study period. This could be because:

1. acute general medical admissions are admitted at another city hospital, therefore acute patients with HIV clinical indicator diseases in whom the neurology component is not a dominant feature would by-pass our unit and be tested for HIV elsewhere;
2. patients admitted to district general hospitals with acute neurological problems are sometimes managed by neurologists without transfer to our unit;
3. despite the increase in HIV testing uptake through our interventions, over half of test-eligible patients were still not tested and therefore could have been missed.

Details of all patients who met local guidelines for HIV test but who were not tested were fed back to their respective neurology consultants for follow-up. It is important that screening continues, as one missed case is costly to public health funds [6]. Moreover, neurological admissions in general are varied and often result in many expensive tests, frequently with a poor return of positive diagnoses e.g. one component of a full vasculitis screen [35].

Barriers to testing for HIV perceived by frontline staff were not investigated in this study, but feedback revealed factors similar to previous studies: HIV stigma [36], variability of uptake amongst consultants [17], inadequate financial and workforce infrastructure [37], and perceived inadequate skill set [20]. The last factor was particularly apparent during the junior doctor teaching sessions, and it has been shown that despite HIV medicine being on the 2009 national core curriculum, over two-thirds of junior doctors still feel they need further training to confidently test for HIV [28, 38].

As with previous studies, our patients were mostly above the age of 50 years [18], in our case the upper limit of the age range being above 80 years as we did not dictate an age ceiling. Previous studies that did so eventually revised their age range of test eligibility: in the Leicester study, all patients newly diagnosed with HIV were above the age of 45 years [17], and three newly diagnosed HIV patients were above the age of 59 in the Croydon study [18]. This reinforces the importance of considering testing in older patients, as they are most likely to be late presenters and be missed for opportunistic HIV testing as they do not necessarily fall into “high-risk” categories [26, 33, 39].
The printed prompt for HIV testing (along with consent) in the neurology clerking pro-
forma improved documentation of consent from 25% to 67.6%, but overall consent was poorly
documented at an average of 35.1% whereas the UKNG mandate documentation of consent in
every patient. A similar audit in another study had a rate of 58% [19].

1 in 8 of our test-eligible patients had conditions not specifically listed in the clinical indica-
tor list. Three patients had unexplained ataxia; our hospital is a national centre of excellence
for ataxia, and pure cerebellar dysfunction as a complication of HIV infection have been
described [40]. Four patients were tested as they presented with atypical optic neuritis, as
defined by local guidelines developed by our neuro-ophthalmology service which recommends
appropriate serology testing in such cases [41]. Three patients had complicated presentations
of headache, including one case with meningism and low-grade fever, one case with cranial
neuropathies and one with ophthalmoplegia not due to acute stroke. In other similar studies,
42–50% of patients who tested positive for HIV had a presentation not listed as an indicator
condition, including presenting with acute headache [17, 18]. Given 10% of acute sero-conver-
sion can present with meningitic or encephalitic features, there is rationale to include routine
testing for HIV in acute non-primary headaches [29].

The data from overall HIV testing rates showed there were 23 HIV tests, approximately one
a month, requested from stroke admissions. We did not audit HIV testing in acute stroke
admissions in our study, but there are recommendations for HIV testing in all acute stroke
patients, particularly in younger patients and cryptogenic cases [42]. We also did not audit
HIV testing in neurology outpatients during our study as we were looking at acute admissions.
Only one previous study looked at outpatient HIV testing in primary care and outpatient set-
tings [20]. Our HIV testing protocol is readily available in our outpatients section, and our
work has been presented within the department to consultants, registrars and junior doctors
who work in clinics in order to reinforce HIV testing in the non-acute patients.

In conclusion, we have demonstrated that a combination of pragmatic interventions has led
to a significantly sustained increase of HIV testing in eligible patients admitted to an acute neu-
rology unit in an area with low HIV prevalence. We have shown that nearly one half of all
acute neurology admissions merit HIV testing according to local guidelines. We strongly rec-
ommend all centres that admit acute neurology cases adopting similar interventions for oppor-
tunistic HIV testing in order to avoid missing neurological presentations of HIV. We also
suggest extending interventions (along with audit) into neurology outpatient settings as we
have to increase HIV testing in non-acute patients.

Acknowledgments

We would like to thank Dr. Mohammed Reza, consultant virologist at Sheffield Teaching Hos-
pitals NHS Foundation Trust, for his help with obtaining HIV testing data. We acknowledge
the contribution of Dr. Chrissie Burness, from The Walton Centre NHS Foundation Trust,
towards drawing up the HIV testing protocol.

Author Contributions

Conceived and designed the experiments: DSS CO NKG DJB. Performed the experiments: DSS
CO RC MF. Analyzed the data: DSS CO RC MF. Contributed reagents/materials/analysis tools:
DSS NKG DJB. Wrote the paper: DSS CO RC MF NKG DJB.

References

1. Aghaizu A, Brown AE, Nardone A, Gill ON, Delpech VC and contributors. HIV in the United Kingdom
2013 Report: data to end 2012. November 2013. Public Health England, London.
2. May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, et al. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS 2014; 28:1193–1202.

3. van-Sighem AI, Gras LA, Reiss P, Brinkman K, de Wolf F. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS 2010; 24:1527–1535.

4. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, Cohen CR, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010; 375:2092–2098.

5. Reynolds SJ, Makumbi F, Nakigozzi G, Kagaayi J, Gray RH, Wawer M, et al. HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy. AIDS 2011; 25:473–477.

6. HIV in the United Kingdom: 2009 Report. Health Protection Agency, 2009.

7. Krentz HB, Auld MC, Gill MJ. The high cost of medical care for patients who present late (CD4 <200 cells/microL) with HIV infection. HIV Medicine 2004; 5: 93–98.

8. 2005–2006 Mortality Audit. BHIVA Audit and Standards Sub-Committee, 2006.

9. Lucas SB, Curtis H, Johnson MA. National review of deaths among HIV-infected adults. Clinical Medicine 2008; 8:250–252.

10. Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recommendations Report: Centers for Disease Control and Prevention (CDC).2006:1–17.

11. Palfreeman A, Fisher M, Ong E, Wardrobe J, Stewart E, Castro-Sanchez E, et al. UK National Guidelines for HIV Testing 2008. British Association for Sexual Health and HIV (BASHH), British HIV Association (BHIVA), British Infection Society (BIS), 2008.

12. Chan SY, Hill-Tout R, Rodgers M, Cormack I. Acceptance of HIV testing in medical inpatients: a local acceptability study. International Journal of STD and AIDS 2011, 22:187–189.

13. Hartney T, Nardone A, Crook P, Figueroa J. Evidence and resources to commission expanded HIV testing in priority medical services in high prevalence areas. Health Protection Agency Report, 2012.

14. Time to test for HIV: Expanding HIV testing in healthcare and community services in England. Health Protection Agency, 2011.

15. Price H, Birchall J, Newey C, Smith F, Waters AM, Mandalia S, et al. HIV opt-out increases HIV testing in low-risk patients. International Journal of STD and AIDS 2009; 20:56–57.

16. Ellis S, Graham L, Price DA, Ong EL. Offering HIV testing in an acute medical admissions unit in Newcastle upon Tyne. Clinical Medicine 2011; 11:541–543.

17. Palfreeman A, Nyatsanza F, Fam H, McKinnon G, Schober P, McNally P. HIV testing for acute medical admissions: evaluation of a pilot study in Leicester, England. Sexually Transmitted Infections. 2013; 89:308–310.

18. Phillips D, Barbour A, Stevenson J, Draper S, Motazed R, Elgalib A. Implementation of a routine HIV testing policy in an acute medical setting in a UK general hospital: a cross-sectional study. Sexually Transmitted Infections 2014; 90:185–187.

19. Peck L, Ferenczi E, Burns F, Cosgrove C, Brown M. Barriers to targeted HIV testing on an acute admissions unit: evaluation of the UK guideline. QJM 2010; 103:147–151.

20. Rayment M, Thornton A, Mandalia S, Elam G, Atkins M, Jones R, et al. HIV testing in non-traditional settings—the HINTS study: a multi-centre observational study of feasibility and acceptability. PLoS One. 2012; 7:e39530.

21. Burns F, Edwards SG, Woods J, Haidari G, Calderon Y, Leider J, et al. Acceptability, feasibility and costs of universal offer of rapid point of care testing for HIV in an acute admissions unit: results of the RAPID project. HIV Medicine 2013; 14(Suppl 3):10–14.

22. Page I, Phillips M, Flegg P, Palmer R. The impact of new national HIV testing guidelines at a district general hospital in an area of high HIV seroprevalence. Journal of the Royal College of Physicians Edinburgh 2011; 41:9–12.

23. Casalino E, Bemot B, Bouchaud O, Alloui C, Choquet C, Bouvet E, et al. Twelve months of routine HIV screening in 6 emergency departments in the Paris area: results from the ANRS URDEP study. PLoS One. 2012; 7:e46437.

24. Chua AC, Leo YS, Cavailler P, Chu C, Ng A, Ng OT, et al. Opt-out of voluntary HIV testing: a Singapore hospital's experience. PLoS One 2012; 7:e34663.

25. Haukoos JS, Hopkins E, Conroy AA, Silverman M, Byyny RL, Eisert S, et al. Routine opt-out rapid HIV screening and detection of HIV infection in emergency department patients. JAMA 2010; 304:284–292.
26. Socias ME, Hermida L, Singman M, Kulgis G, Diaz Armas A, Cando O, et al. Routine HIV testing among hospitalized patients in Argentina. Is it time for a policy change? PLoS One 2013; 8:e69517.
27. Perry NH, Cassell J. HIV testing in acute general medical admissions must be universally offered to reduce undiagnosed HIV. HIV Medicine 2010; 11:0-19.
28. Alston CM, Asherson A, Powell N, Narouz N. HIV testing in medical admissions is a missed opportunity. Clinical Medicine 2013; 13:114.
29. Gendelman HEG, Grant I, Everall IP, Fox HS, Gelbard HA, Lipton SA, et al. The Neurology of AIDS. Third edn.: Oxford University Press, 2011.
30. Solomon T, Michael BD, Smith PE, Sanderson F, Davies NW, Hart IJ, et al. Management of suspected viral encephalitis in adults: Association of British Neurologists and British Infection Association National Guidelines Journal of Infection 2012; 64:347–373.
31. SOPHID. Survey of prevalent HIV infections diagnosed 2011. Health Protection Agency, 2011.
32. Sokhi D, Oxenham C, Blackburn D, Gupta N, Price S. Audit of the impact of an HIV testing protocol for acute neurology admissions to a tertiary centre. HIV Medicine 2013; 4(Suppl 2):12–77.
33. Ratcliffe L, Thomas S, Beeching NJ, Phillips-Howard PA, Taegtmeyer M. Acute presentations of HIV are still missed in low prevalence areas. Postgraduate Medical Journal 2011; 87:170–174.
34. Dodd MC, Collini PJ, Dockrell DH. Low concordance with HIV testing guidelines in a retrospective review of intensive care practice. Thorax 2013; 68:1072–1074.
35. McLaren JS, Stimson RH, McRorie ER, Coia JE, Luqmani RA. The diagnostic value of anti-neutrophil cytoplasmic antibody testing in a routine clinical setting. QJM. 2001; 94:615–621.
36. Thornton AC, Rayment M, Elam G, Atkins M, Jones R, Nardone A, et al. Exploring staff attitudes to routine HIV testing in non-traditional settings: a qualitative study in four healthcare facilities. Sexually Transmitted Infections 2012; 88:601–606.
37. Deblonde J, De-Koker P, Hamers FF, Fontaine J, Luchters S, Temmerman M, et al. Barriers to HIV testing in Europe: a systematic review. European Journal of Public Health 2010; 20:422–432.
38. Mitchell L, Bushby SA, Chaunhan M. An audit highlighting a lack of awareness of the UK national guidelines for HIV testing, 2008. International Journal of STD and AIDS 2011; 22:753–754.
39. Buetikofer S, Wandeler G, Kouyos R, Weber R, Ledergerber B. Prevalence and risk factors of late presentation for HIV diagnosis and care in a tertiary referral centre in Switzerland. Swiss Medical Weekly 2014; 144:w13961.
40. Anand KS, Wadhwa A, Garg J. A Case of Cerebellar Ataxia Associated with HIV Infection. J Int Assoc Provid AIDS Care. 2014; 13:409–10
41. Hickman S, Ko M, Chaudry F, Jay WM, Plant GT. Optic Neuritis: An update. Typical and Atypical Optic Neuritis. Neuro-Ophthalmology. 2008; 32:237–248
42. Benjamin LA, Bryer A, Emsley HC, Khoo S, Solomon T, Connor MD. HIV infection and stroke: current perspectives and future directions. Lancet Neurology 2012; 11:878–890.